MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer

F. Pietrantonio, D. Oddo, A. Gloghini, Emanuele Valtorta, R. Berenato, L. Barault, M. Caporale, A. Busico, F. Morano, A.V. Gualeni, A. Alessi, G. Siravegna, F. Perrone, M. Di Bartolomeo, A. Bardelli, F. De Braud, F. Di Nicolantonio

Research output: Contribution to journalArticlepeer-review

Cite this